Log in

Start Your Membership Now

January 1, 2011 The National Institute for Health and Clinical Excellence (NICE) recently recommended that general practitioners in England and Wales provide treatment for patients with mild Alzheimer’s disease; previously, NICE limited treatment to patients with moderate or severe impairment due to Alzheimer’s. Patients with mild impairment were permitted to return for reassessment only when their condition deteriorated. The new recommendation will permit individuals with mild cognitive impairment to obtain medications to reduce the symptoms. NICE guidelines recommended donepezil, galantamine, revastigmine, and memantine. Download the Report . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Market Intelligence Resource | January 1, 2011

NICE Final Appraisal Determination

January 1, 2011 The National Institute for Health and Clinical Excellence (NICE) recently recommended that general practitioners in England and Wales provide treatment for patients with mild Alzheimer’s disease; previously, NICE limited treatment to patients with moderate or severe impairment due to Alzheimer’s. Patients with mild impairment were permitted to return for reassessment only when their condition deteriorated. The new recommendation will permit individuals with mild cognitive impairment to obtain medications to reduce the symptoms. NICE guidelines recommended donepezil, galantamine, revastigmine, and memantine. Download the Report . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.